Form 4: Lemaitre Vascular Executive Acquires Dividend Rights

Lemaitre Vascular's Senior VP of Operations, Trent G. Kamke, acquired dividend equivalent rights tied to existing equity awards.

Summary

• Trent G. Kamke, Senior V.P., Operations at LEMAITRE VASCULAR INC (LMAT), acquired a total of 10.0638 Dividend Equivalent Rights (DERs) on March 26, 2026.
• These DERs accrued on various previously granted Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards.
• Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• The DERs vest proportionately with their underlying RSU and PSU awards.
• Following these transactions, Kamke beneficially owns a total of 59.7029 Dividend Equivalent Rights directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a routine compensation update that reinforces executive alignment with shareholder interests but does not represent new capital investment or a significant change in company fundamentals.

Positives

• The acquisition of Dividend Equivalent Rights aligns the executive's interests with those of shareholders, as the value of these rights is tied to the company's common stock.
• This is a routine part of executive compensation, indicating ongoing commitment and retention of key management.

Negatives

• No direct cash investment or purchase of common stock by the insider was reported, as these are accrued rights rather than open market purchases.

Future Outlook

The Dividend Equivalent Rights will vest proportionately with their underlying Restricted Stock Unit and Performance Share Unit awards, indicating future potential for conversion into common stock upon vesting.

Industry Context

StockSavvy.ai notes that the accrual of dividend equivalent rights on equity awards is a common component of executive compensation packages in the medical device and broader corporate sectors. This practice aims to ensure that executives benefit from dividends declared on shares underlying their unvested awards, further aligning their financial interests with those of long-term shareholders.

Comparison to Industry Standards

• The structure of granting Dividend Equivalent Rights alongside RSUs and PSUs is a standard practice in executive compensation across various industries, including medical technology companies like Medtronic, Abbott Laboratories, and Boston Scientific, which often use similar equity-based incentives to attract and retain talent.
• The specific amounts of DERs are proportional to the underlying equity awards, which are typically benchmarked against peer group compensation data to ensure competitiveness and fairness.

Stakeholder Impact

• Shareholders: The accrual of DERs aligns executive incentives with shareholder returns, as the value is tied to common stock performance and dividends.
• Employees: This reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• The Dividend Equivalent Rights will continue to vest in accordance with the schedules of their underlying Restricted Stock Unit and Performance Share Unit awards.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the accrual of dividend equivalent rights. It does not provide new information that would fundamentally alter the investment thesis for Lemaitre Vascular. While it indicates continued alignment of executive interests with shareholders, it is not a catalyst for a 'buy' or 'sell' recommendation. Investors should continue to 'hold' based on broader company performance and market conditions.

Keywords

Lemaitre Vascular, LMAT, Insider Transaction, Form 4, Dividend Equivalent Rights, Executive Compensation, Restricted Stock Units, Performance Share Units, Trent G. Kamke